Kidd’s Stuttering Act

The Kidd's Stuttering Act (HR6364) was introduced in the House on December 2, 2025, and subsequently referred to the House Committee on Energy and Commerce. This bill is in the early stages of the legislative process. Its primary aim is to amend titles XI, XIX, and XXI of the Social Security Act to require Medicaid and CHIP coverage for screenings for childhood-onset fluency disorders and certain speech therapy services. This legislative action, if passed, would establish a new, guaranteed revenue stream for providers of these services. The bill does not specify a direct funding amount; rather, it mandates coverage under existing federal programs (Medicaid and CHIP). This means that while no new appropriations are authorized by this specific bill, it would significantly increase the demand for services that health insurers manage and diagnostic companies provide. The mechanism is a mandate for coverage, which would lead to increased utilization and reimbursement for speech-language pathology services, funded through the existing Medicaid and CHIP structures. This represents an expansion of covered services rather than a direct federal appropriation to specific entities. Structural winners, should this bill advance, include health insurers that administer Medicaid and CHIP plans, such as UnitedHealth Group ($UNH), Elevance Health, Inc. ($ELV), and Humana Inc. ($HUM), as they would manage the increased volume of claims. Diagnostic companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) could also see increased demand for related diagnostic screenings. CVS Health Corporation ($CVS), through its Aetna health insurance segment, would also be impacted. The bill's requirement for screenings for children aged 2-6 starting January 1, 2027, suggests a future increase in service demand. Recent market data shows that health insurers have experienced varied performance. UnitedHealth Group ($UNH) is currently at $281.36, up 7.48% over the last 7 days but down 2.57% over the last 30 days. Elevance Health, Inc. ($ELV) is at $302.61, up 6.26% over 7 days and 5.63% over 30 days. Humana Inc. ($HUM) is at $182.65, up 10.03% over 7 days and 1.05% over 30 days. Diagnostic companies Labcorp Holdings Inc. ($LH) is at $274.46, up 4.12% over 7 days and down 0.53% over 30 days. Quest Diagnostics Incorporated ($DGX) is at $198.96, up 0.91% over 7 days and down 2.46% over 30 days. The bill is currently in committee, meaning it must pass through committee, be voted on by the House, then potentially the Senate, and finally signed by the President to become law.